Expert consensus document: A 'diamond' approach to personalized treatment of angina. by Ferrari, R et al.
Chronic stable angina pectoris is the most prevalent 
symptomatic manifestation of ischaemic heart dis-
ease, and its management is a priority (BOX 1). Current 
clinical guidelines recommend antianginal therapy to 
control symptoms, before considering coronary artery 
revasculariza tion1–4. However, revascularization by 
either percutaneous coronary angioplasty or CABG 
surgery is indicated in patients who have significant 
artery steno sis (50% left main narrowing or proximal 
three-vessel disease) to reduce myocardial ischaemia 
and its adverse clinical manifestation. Antianginal 
agents are approved by documenting that they improve 
total exercise duration, together with a reduction in 
daily frequency of chronic stable angina compared with 
placebo and/or equivalence to an active comparator. 
Cardiovascular outcomes, although highly advocated, 
are not a pre requisite for regulatory approval. None of 
the antianginal drugs has been proved to reduce cardio-
vascular mortality or the rate of myocardial infarc-
tion. When patients are optimally treated, mortality 
for chronic stable angina is low, which might explain 
why all trials designed to improve prognosis have been 
negative. Guidelines recom mend a first-choice and a 
second-choice approach, based more on tradition and 
expert opinion, rather than evidence. This categorical 
approach has been questioned in the past couple of 
years5–8. Newer antianginal drugs, which are classified 
as second choice, have more evidence-based clinical data 
that are more contemporary to support their use than is 
available for the traditional first-choice drugs. Equally, 
the often-needed combin ation of double or triple ther-
apy is based on expert opinion and not related to the 
underlying pathophysio logy. What constitutes optimal 
antianginal treatment, therefore, varies considerably 
between countries, and the majority of doctors treat 
their patients according to their own preconceptions.
A group of experts with experience and interest in 
chronic stable angina met at the University of Ferrara, 
Italy, to discuss an individualized approach to med-
ical treatment of chronic stable angina, on the basis 
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Abstract | In clinical guidelines, drugs for symptomatic angina are classified as being first choice 
(β‑blockers, calcium‑channel blockers, short‑acting nitrates) or second choice (ivabradine, 
nicorandil, ranolazine, trimetazidine), with the recommendation to reserve second‑choice 
medications for patients who have contraindications to first‑choice agents, do not tolerate them, 
or remain symptomatic. No direct comparisons between first‑choice and second‑choice 
treatments have demonstrated the superiority of one group of drugs over the other. 
Meta‑analyses show that all antianginal drugs have similar efficacy in reducing symptoms, 
but provide no evidence for improvement in survival. The newer, second-choice drugs have more 
evidence‑based clinical data that are more contemporary than is available for traditional 
first‑choice drugs. Considering some drugs, but not others, to be first choice is, therefore, 
difficult. Moreover, double or triple therapy is often needed to control angina. Patients with 
angina can have several comorbidities, and symptoms can result from various underlying 
pathophysiologies. Some agents, in addition to having antianginal effects, have properties that 
could be useful depending on the comorbidities present and the mechanisms of angina, but the 
guidelines do not provide recommendations on the optimal combinations of drugs. In this 
Consensus Statement, we propose an individualized approach to angina treatment, which takes 
into consideration the patient, their comorbidities, and the underlying mechanism of disease.
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of the underlying physiopathology and comorbidities. 
We reached the consensus that a ‘diamond’ approach 
is more appropriate than current recommendations to 
guide clinicians in selecting the most suitable drug regi-
men, alone or in combination, for an individual patient. 
Thus, the diamond diagram (FIG. 1) has become a theme 
of this Consensus Statement. As in hypertension, the 
idea of a diamond approach leaves treating physicians 
free to choose the most appropriate drugs, according to 
a patient’s needs.
Pathophysiology
Various pathophysiological entities can cause myo-
cardial ischaemia and, therefore, its symptom: chronic 
stable angina (FIG. 2). Chronic stable angina can be 
divided into three major categories: stable, vasospastic, 
and microvascular.
Chronic stable angina is precipitated by exercise- 
induced or emotional stress-induced ischaemia in 
patients with coronary flow-limiting atherosclerotic 
stenosis in the large coronary arteries. Several factors 
contribute to an increase in myocardial oxygen demand, 
the most important being changes in heart rate, blood 
pressure or afterload, myocardial wall tension, cardiac 
hypertrophy, and myocardial contractility. Conversely, 
the major determinants of oxygen delivery include coro-
nary blood flow, which, in turn, depends on the pressure 
gradient across the coronary circuit and the integrity of 
the coronary arteries, as well as on the oxygen-carrying 
capacity of the blood and the haemoglobin level.
The heart is extremely dependent on adequate oxy-
gen delivery to allow the physiological production of 
energy (in the form of ATP) to support its contraction 
and basal metabolism. In 1 day, the human heart per-
forms about 100,000 beats, pumps about 9,000 l of blood 
around the circulation, and uses a considerable amount 
of ATP (estimated at 16–30 kg), which is produced by 
the mitochondrial oxidation of acetyl-CoA and immedi-
ately utilized to allow contraction of the myofilaments in 
systole and calcium extrusion in diastole. This energy 
usage explains the high number of mitochondria in 
the heart, the high capacity (70–80%) of the myocytes 
to extract oxygen from the arterial blood, and why the 
heart depends on oxygen delivery through the coronary 
arteries. Under physiological conditions, an increased 
oxygen demand is met by an increase in coronary blood 
flow as a consequence of dilatation of coronary arteries, 
which does not occur in patients with atherosclerotic 
lesions of epicardial coronary arteries.
The concept that chronic stable angina is caused by 
epicardial stenosis has been challenged on the basis of 
various observations. In a fraction of patients, myo-
cardial ischaemia can persist or reoccur after having 
undergone successful complete coronary revasculariza-
tion9,10. Outcome analyses show little or no prognostic 
effect of elective angioplasty11. Autopsy studies of patients 
with chronic stable angina suggest that coronary artery 
obstruction is not necessarily synonymous with myo-
cardial ischaemia12. Therefore, it seems that myocardial 
ischaemia can occur in the absence of obstructive epi-
cardial and coronary atherosclerosis. In the majority of 
these cases, chronic stable angina is caused by coronary 
microvascular dysfunction. This condition, previously 
known as cardiac syndrome X, is named microvascular 
angina, which often pertains to women with symptoms of 
chronic stable angina, normal or near-normal coronary 
arteries, and evidence of ischaemia during stress testing 
or during acetylcholine testing13,14. Increasing attention 
has been focused on the recognition of this condition, 
and microvascular angina might occur in up to 40% 
of patients with angina, depending on the studies15–17. 
This high percentage, however, includes patients with 
the symptoms of chronic stable angina with suspected 
ischaemia, but without a clear demonstration of it.
Another circumstance in which the coronary arter-
ies might appear normal under coronary angiography 
is with vasospastic angina. This condition occurs in 
a minority of patients, and is caused by an abnormal 
reactivity of the smooth muscles of the coronary arter-
ies (which, therefore, cannot be considered functionally 
normal)18. This form of angina presents with specific 
characteristics — pain is not triggered by exercise, but 
occurs at rest. Vasospasm can be evoked by different 
 triggers and needs specific diagnostic tests and thera-
pies18. A certain degree of coronary spasm might also be 
superimposed on a nonocclusive, fixed athero sclerotic 
stenosis, which becomes occlusive and  therefore 
 symptomatic when the smooth muscle constricts.
The various causes and mechanisms of chronic 
 stable angina without obstructive coronary artery dis-
ease can be grouped into three broad categories: non-
cardiac,  cardiac nonischaemic, and cardiac ischaemic 
causes (FIG. 3).
Drug therapy
The management of chronic stable angina encompasses 
lifestyle modification, control of risk factors for coro-
nary artery disease, and both invasive and noninvasive 
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treatment1–4. Pharmacological therapy has two main 
goals: firstly to alleviate symptoms, increase angina-free 
walking time, and improve quality of life; and secondly 
to prevent cardiovascular events, mainly myocardial 
infarction and death. Unfortunately, evidence-based 
studies indicate that these two goals cannot be achieved 
with the same class of drugs — pharmacological therapy 
to prevent cardiovascular events (aspirin, statins, and 
angiotensin-converting-enzyme inhibitors) does not 
alleviate symptoms and, similarly, symptomatic therapy 
does not improve prognosis.
In this Review, we consider only the drug thera-
pies to reduce the symptoms of chronic stable angina 
(TABLE 1). We summarize the most relevant features of the 
guideline- recommended drugs, with the aim of empha-
sizing the different characteristics in terms of mech-
anism of action, adverse effects, and peculiarities that 
allow treatment to be targeted to individual patients. 
A combin ation of two or more of anti-ischaemic drugs 
with additive or synergistic effects is often needed to 
control symptoms effectively. These combinations 
should also be tailored to the type of chronic stable 
angina and to the individual patient (FIG. 1).
Nitrates. Nitrates are organic products that, in the vessel 
wall, undergo enzymatic denitrification by mitochon-
drial aldehyde dehydrogenase, producing vasoactive 
nitric oxide, which causes vasodilatation19. At low doses, 
nitrates are predominantly venodilators and thus reduce 
preload and venous return to the heart with reductions 
in ventricular volume and myocardial wall tension, 
leading to a decrease in myocardial oxygen demand. 
At higher doses, nitrates also dilate coronary arter-
ies, prevent coronary spasm, improve subendocardial 
blood flow to the ischaemic areas, decrease ventricular 
diastolic pressure, and lower blood pressure20. In addi-
tion, nitrates improve collateral blood flow. The effects 
on preload and afterload are often partly offset by an 
increase in heart rate and myocardial contractility owing 
to reflex sympathetic activity. Combining nitrates with 
β-blockers can be useful to block tachycardia, leading to 
a synergetic anti-ischaemic effect1,2 (FIG. 1).
The most important adverse effects of nitrates are 
headache, flushing, palpitations, and hypotension. These 
effects are caused by vasodilatation of intracranial and 
extracranial vessels, leading to reflex tachycardia. Rare 
cases of syncope might occur in the elderly owing to 
profound hypotension associated with bradycardia. All 
these adverse effects are dose-dependent. Consequently, 
nitrates should be titrated to control chronic stable 
angina at the lowest possible dose. Nitrates are contra-
indicated in patients with hypertrophic obstructive 
cardiomyopathy, severe aortic or mitral stenosis, 
or con strictive pericarditis, because they reduce venous 
return, increase outflow gradient, and reduce cardiac 
output, and are also contraindicated in patients with 
closed-angle glaucoma21. Concomitant administration of 
phosphodiesterase 5 inhibitors (used for the treatment 
of erectile dysfunction or pulmonary hypertension) 
greatly potentiates the vasodilator effect of nitrates.
Key points for nitrates:
• Several meta-analyses showed no differences in symp-
tom relief or exercise-testing parameters between 
nitrates and other antianginal agents22–24.
• No data are available to support the concept that 
nitrates improve outcomes in patients with chronic 
stable angina.
• The vasodilatory effects of nitrates are independent 
from the integrity of the endothelium as they undergo 
bioconversion into nitric oxide both in the endothelial 
cells of the vessel and in the myocytes, by a mechanism 
that is still not fully elucidated. This finding could be 
relevant in patients with micro vascular angina, which 
is characterized by dysfunction of the endothelium, 
but when tested in these subgroups of patients, the 
results have been disappointing25. Furthermore, 
small arterioles are nitrate-resistant, which explains 
why nitrates have no action in the microcirculation 
and evoke less reflex tachycardia than nitroprusside, 
a direct nitric oxide donor26.
• Patients with microvascular or macrovascular angina 
might also have an overlapping spasm. In these 
patients, nitrates provide a clear benefit in terms of 
reduction of symptoms.
• In patients with chronic stable angina, long-term 
nitrates should be used with caution, together with 
other vasodilators.
β‑Blockers. β-Blockers bind to G-proteins, which are 
linked to β-adrenergic receptors, thus inhibiting the 
effects of adrenaline and noradrenaline on these recep-
tors27. In patients with chronic stable angina,  β-blockade 
reduces ischaemic burden by lowering heart rate and 
myocardial contractility, especially during exercise, 
as well as by preventing the exercise-induced increase 
in blood pressure. These changes result in a reduction in 
oxygen demand at rest and during exercise. Slowing heart 
rate leads to increased diastolic time and coronary per-
fusion, thus improving oxygen supply27. Other features 
of β-blockers include a reduction in atrio ventricular 
conduction and ectopic activity, as well as an attenuation 
of the release of renin from the juxtaglomerular cells, 
Box 1 | Epidemiology and prognosis of chronic stable angina
• The prevalence and incidence of chronic stable angina vary according to the diagnostic 
criteria used
• In Western countries, an estimated 30,000–40,000 people per million of the population 
have chronic stable angina98
• The prevalence increases with age in both sexes: estimates range from 5–7% in 
women aged 45–64 years to 10–12% in women aged 65–84 years; and from 4–7% 
in men aged 45–64 years to 14–15% in men aged 65–84 years1
• The incidence of chronic stable angina is 1% for Western male population aged 
45–65 years, with a slightly higher incidence in women1
• The prevalence and incidence of chronic stable angina is anticipated to increase in 
the coming decade as a result of the ageing population, the epidemic of obesity and 
other risk factors, the increasing use of life-prolonging therapies, and the improved 
management of acute coronary syndromes99
• Approximately 4.1 million deaths from coronary artery disease occur in Europe each 
year, with 82% in people aged >65 years, and 46% in those aged >75 years; the annual 
death rate is 1.2–2.4%1,2
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and indirect improvement of myocardial energetics by 
inhibiting catecholamine-induced release of free fatty 
acids from adipose tissue.
Several subtypes of β-blockers exist:  nonselective, 
without intrinsic sympathomimetic activity (such as 
propanolol, sotalol, timolol); nonselective, with intrin-
sic sympathomimetic activity (oxyprenolol, pindo-
lol);  β1-selective (atenolol, bisoprolol, metoprolol); 
 β1-selective with α-blocking activity (carvedilol, 
labetalol); and β1-selective with nitric oxide-mediated 
vasodilatory properties (nebivolol)28.
Although generally well-tolerated, β-blockers share 
a range of adverse effects, the majority of which are 
directly related to β-blockade. These effects include 
bradycardia, hypotension, bronchospasms, and blunting 
of the tachycardia response to hypoglycaemia. Particular 
caution should be exercised in women who are preg-
nant, and in patients with low systolic blood pressure, 
Raynaud syndrome, or diabetes mellitus27. Adverse 
effects unrelated to β-blockade are depression, lethargy, 
constipation, and impotence28. The reported incidence 
of erectile dysfunction has been questioned, and the 
magnitude of the effect remains unclear27. β-Blocker 
treatment should not be abruptly discontinued because 
upregulation of β-adrenoceptors could lead to severe 
tachycardia and vasoconstriction, with precipitation of 
acute coronary syndromes27. Equally, β-blockers should 
not be prescribed to patients with vasospastic angina 
because they can precipitate α-mediated vasospasm28.
Key points for β‑blockers:
• The efficacy of β-blockers to control chronic  stable 
angina is similar to that of the other antianginal 
drugs22–24.
• In clinical practice, β-blockers are often combined 
with dihydropyridine calcium-channel blockers and 
other vasodilating antianginal agents to enhance their 
anti-ischaemic effect27.
• β-Blockers should not be combined with verapa-
mil, and only with caution with diltiazem, because 
of the risk of bradycardia or atrioventricular block 
and hypotension, but can be combined with ivabra-
dine to reduce heart rate further and to improve 
exercise duration29.
• β-Blockers should be the preferred treatment in 
patients with reduced left ventricular ejection frac-
tion (<40%) or with post-infarct angina, or heart 
failure. Several randomized clinical trials in this 
subset of patients have shown an improvement in 
angina associ ated with a reduction in cardiovascular 
 mortality and sudden death30,31.
• β-Blockers should be the first-choice treatment in 
patients with chronic stable angina and high blood 
pressure and heart rate, history of supraventricular 
tachycardia including atrial fibrillation, or hyper-
trophic cardiomyopathy. These suggestions are 
reason able and are made by experts, but no specific 
trials have been carried out in these populations.
• Traditionally, β-blockers are considered to be cardio-
protective in patients with stable coronary artery dis-
ease, independently from left ventricular dysfunction. 
This assumption is not supported by evidence, and is 
extrapolated from data obtained in the early 1980s in 
patients after myocardial infarction, in the era before 
revascularization and in the absence of treatment with 
angiotensin-converting-enzyme inhibitors and stat-
ins32. Clinical and observational research shows that 
the beneficial prognostic effect of heart-rate-lowering 
drugs, such as β-blockers (and ivabradine), depends on 
the effects of reduced heart rate on the damaged myo-
cytes, with improvement of ventricular remodelling33. 
In the majority of patients with chronic stable angina, 
ventricular function is preserved, with no remodelling 
process. In these patients, β-blockers do not improve 
outcome, as shown in contemporary observational 
studies31,33–35. Accordingly, the guidelines have, over the 
years, limited the prognostic usefulness of β-blockade 
in patients with chronic stable angina.
• Nonselective, and also to some extent selective, 
 β-blockers can result in coronary  constriction by caus-
ing a shift from β-adrenoreceptors to α-adreno-
receptors. Under these circumstances, catecholamines 
bind preferentially to the α-adrenoreceptors causing 
vasoconstriction. β-Blockers are contra indicated in 
vasospastic angina, and not useful in  microvascular 
angina.
Calcium‑channel blockers. Calcium-channel block-
ers are classified according to their structure as being 
dihydro pyridines (amlodipine, felodipine, nifedipine, and 
nisoldipine) or nondihydropyridines (diltiazem and ver-
apamil). All these drugs inhibit calcium influx through 
the high-voltage-activated L-type calcium channel, 
located in the smooth muscle of the arterial wall and 
on the myocardium, leading to smooth  muscle relax-
ation and reduction of myocardial contractility. The 
different agents have different selectivity for L-type 
calcium channels in the vasculature and myocardium27. 
Dihydropyridines have high selectivity for L-type 
channels of the vasculature and produce a decrease in 
coro nary and systemic vascular resistance. They exert 
an antianginal action by reducing oxygen demand and 
Nature Reviews | Cardiology
Calcium-channel blockers
β-Blockers Ivabradine
Ranolazine
Dilitiazem, verapamil
Trimetazidine
Nitrates, nicorandil
Figure 1 | Possible combinations of different classes of antianginal drugs. 
The schematic shows useful combinations (green lines), combinations that are not 
recommended (red lines), possible combinations (blue solid lines), and drugs with similar 
actions (blue dashed lines).
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improving coronary dilatation. Reflex tachycardia is not 
uncommon, especially with short-acting dihydropyri-
dines. Diltiazem and verapamil are less selective for the 
vasculature than the dihydropyridines, and have more 
pronounced effects on myocardial contractility as well 
as cardiac pacemaker and atrioventricular conduction 
cells, leading to negative inotropic and chronotropic 
effects. Their antianginal action is owing to a reduction 
in oxygen demand because of reductions in afterload, 
heart rate, and myocardial contractility.
The major adverse effects, particularly for dihydro-
pyridines, are systemic hypotension, headache, dizzi-
ness, flushing, palpitations, and leg oedema, the last 
being common to all calcium-channel blockers27. Owing 
to their intrinsic negative inotropic effects, diltiazem and 
verapamil might also reduce left ventricular contractil-
ity. Verapamil decreases intestinal motility leading to 
 constipation, especially in elderly individuals.
Key points for calcium‑channel blockers:
• The antianginal efficacy of all calcium-channel block-
ers is similar to that of the other antianginal drugs22–24.
• All calcium-channel blockers are effective alone 
or in combination with nitrates in the treatment of 
 vasospastic angina36.
• Calcium-channel blockers do not improve survival of 
patients with chronic stable angina with or without 
myocardial infarction or left ventricular dysfunction 
and, when used in patients with heart failure, they 
might have deleterious effects on outcome37,38.
• All calcium-channel blockers are metabolized in the 
liver by cytochrome P450 3A4, the same enzyme that 
metabolizes ivabradine. Diltiazem and verapamil 
should, therefore, not be used in combination with 
ivabradine owing to the risk of severe bradycardia39.
Nicorandil. Nicorandil is a nicotinamide nitrate ester 
and an adenosine-sensitive potassium-channel opener 
with nitric oxide donor capacity40. Nicorandil exerts an 
antianginal effect by increasing coronary blood flow, 
preventing coronary artery spasms, and causing arterial 
vasodilatation. Therefore, as with nitrates and dihydro-
pyridine calcium-channel blockers, nicorandil improves 
the balance of oxygen demand and delivery. Additionally, 
as a consequence of its capacity to open ATP-sensitive 
potassium channels, nicorandil exerts some metabolic 
effects and a form of preconditioning on the myo-
cardium41. The antianginal action has been assessed in 
small and dated randomized trials with mixed results41–43. 
The main adverse effects of nicorandil are headache, 
reflux, tachycardia, facial flushing, and hypotension. 
Rarely, serious skin, mucosal, and eye ulceration have 
also been reported43.
Key points for nicorandil:
• Nicorandil is associated with some improvements 
in outcomes. In the randomized, controlled IONA 
outcome study44, nicorandil significantly reduced the 
composite primary end point of cardiovascular death, 
nonfatal myocardial infarction, or unplanned admis-
sion to hospital for chest pain, despite 39% of patients 
in the treatment group withdrawing because of head-
ache. Of note, the IONA trial44 showed no signifi cant 
reduction in the two most important components 
of the primary end point: cardiovascular mortality 
and myocardial infarction. The beneficial effects 
were driven by a reduction in unplanned hospitaliza-
tion for unstable angina, which is an indication of 
reduced angina although, unexpectedly, nicorandil 
did not improve chronic stable angina in the study. 
A larger beneficial effect of nicorandil was recorded 
in a propensity- matched cohort of 5,115 Japanese 
patients with chronic stable angina who were followed 
up for 7 years.
• The concomitant use of nicorandil with aspirin 
might increase the risk of gastrointestinal ulcers, 
 perforations, and haemorrhage43.
Ivabradine. By inhibiting the If current, ivabradine 
reduces the slope of the slow diastolic depolarization 
phase of the action potential in sinus node cells, thereby 
selectively reducing heart rate. The If inhibition is ‘use- 
dependent’, and the heart-rate reduction with ivabradine 
is greater when initial heart rate is high, and lower when 
the initial heart rate is low45. Ivabradine has no negative 
inotropic or lusitropic effect45. The ivabradine-induced 
Nature Reviews | Cardiology
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Figure 2 | Different manifestations of myocardial ischaemia. Stable angina occurs 
when myocardial ischaemia is caused by fixed atherosclerotic nar owing of one o  more 
epicardial coronary arteries. In some circumstances, the angina is associated with a 
coronary spasm and metabolic dysfunction. Vasospastic angina occurs when myocardial 
ischaemia is caused by a coronary artery spasm with or without endothelial dysfunction. 
Microvascular angina refers to the absence of an obstructed epicardial coronary artery. 
Myocardial ischaemia in this case can be caused by microvascular and/or endothelial 
dysfunction and inflammation.
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reduction in heart rate is similar to that with  β-blockers, 
but with maintenance of coronary dilatation during exer-
cise46. In addition, ivabradine increases coronary flow 
reserve and collateral perfusion, promoting the develop-
ment of coronary collaterals and maintaining endothe-
lial function in patients with chronic stable angina47,48. 
The antianginal effects of ivabradine have been docu-
mented in several randomized clinical trials against 
placebo, various active comparators, and in addition 
to  β-blockers, as well as in unselected studies reflecting 
 routine clinical practice29,49.
Adverse effects of ivabradine are bradycardia and 
phosphenes. Occurrence of bradycardia was reported 
in 2.2–4.2% of patients with chronic stable angina. The 
rate of bradycardia was much higher (18.0%) in the 
SIGNIFY  trial39. Of note, the therapeutic regimen 
in SIGNIFY (7.5 mg uptitrated to 10.0 mg twice daily) 
significantly differs from current clinical practice, and 
4.6% of patients were treated with diltiazem or verapamil, 
which are moderate inhibitors of cytochrome P450 P3A4, 
which metabolizes ivabradine. This inhibition might have 
contributed to the excess bradycardia. In SHIFT50, involv-
ing 6,558 patients with chronic heart failure, despite the 
frailty of the patients and that 89% were taking  β-blockers, 
treatment withdrawal owing to  bradycardia occurred in 
only 1% of the overall population.
The visual symptoms induced by ivabradine are 
caused by the presence of If channels in the retina that 
closely resemble the If channels of the sinus node. The 
observed phosphenes are reported to occur in 5.4% of 
patients, are mild and transitory, and only rarely lead to 
treatment withdrawal (<1%)39.
Treatment with ivabradine also seems to increase the 
absolute incidence of atrial fibrillation by 0.7%51. The 
majority of cases of emergent atrial fibrillation in the 
SIGNIFY trial39 were paroxysmal in nature and managed 
according to current European guidelines.
Key points for ivabradine:
• The antianginal efficacy of ivabradine is similar to 
that of other classes of antianginal agents52,53.
• Ivabradine provides additional benefits when used in 
combination with the other antianginal drugs (except 
diltiazem and verapamil), including β-blockers29.
• The synergistic effect between β-blockers and ivabra-
dine suggests that in patients receiving treatment 
with β-blockers who are still symptomatic, add-
ing  ivabradine is more efficient than uptitration of 
β-blockers54.
• The SIGNIFY trial39 data confirm that ivabradine 
improves symptoms of chronic stable angina, but does 
not affect outcomes in patients with preserved left 
ventricular function. In the prespecified chronic stable 
angina subgroup (Canadian Cardiovascular Society 
class ≥2; 12,000 patients), an increase seemed to 
occur in the primary composite end point of cardio-
vascular death and nonfatal myocardial infarction. 
Of note, however, this subgroup analysis of a neutral 
trial should be interpreted with caution. In any case, 
the explanation of these results could be the higher 
dosage used in the trial and/or the concomitant use of 
diltiazem or verapamil. The Pharmacovigilance Risk 
Assessment Committee of the European Medicines 
Agency concluded after revision of the SIGNIFY data 
that, at an appropriate dose (up to 7.5 mg twice daily), 
ivabradine is a useful therapeutic option to relieve 
symptoms and improve quality of life in suitable 
patients with chronic stable angina in sinus rhythm 
with a heart rate ≥70 bpm who cannot tolerate or 
whose symptoms are inadequately controlled with 
β-blockers55.
• The BEAUTIFUL trial56,57 assessed the effects of iva-
bradine on clinical outcomes. The primary end point 
(combination of cardiovascular death and hospitaliza-
tion for myocardial infarction or for new-onset or 
worsening heart failure) was not improved by ivabra-
dine. In a prespecified subgroup analysis of patients 
with chronic stable angina at entry, ivabradine 
reduced the rate of myocardial infarction58. These 
data need to be considered with great caution, as they 
are the results of a subgroup analysis of a neutral trial.
Nature Reviews | Cardiology
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Figure 3 | Aetiology of chest pain without obstructive coronary artery disease. 
Various causes of angina without obstructive coronary artery disease are shown. 
Noncardiac pain can be caused by: gastro‑oesophageal reflux, musculoskeletal 
alterations, pulmonary and aortic diseases, psychiatric conditions, or inappropriate 
perception of chest pain. Causes of nonischaemic cardiac pain are: pericarditis, pericardial 
diseases, and arrhythmias. As for the cardiac ischaemic group, spasm of epicardial 
coronary arteries owing to smooth muscle dysfunction was recognized as an adjunctive, 
functional mechanism of transient myocardial ischaemia and angina. Heightened 
sensitivity of the coronary microcirculation to vasoconstrictor stimuli associated 
with a limited microvascular vasodilator capacity might also be the cause 
of microvascular angina, together with mismatch between metabolic signalling 
and microvascular adaptation. Other causes include dysfunction of endothelial cells of the 
microvascular network, most likely owing to increased oxidative stress and inflammation.
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• A 2016 analysis of patients with ischaemic heart dis-
ease and chronic stable angina enrolled in SHIFT59 
shows that the outcome benefits of ivabradine were 
 maintained for the duration of follow-up (22.9 months).
Ranolazine. Ranolazine is an active piperazine derivative 
that is structurally related to trimetazidine60. The exact 
mechanism of action of ranolazine is difficult to elucid-
ate. Firstly, like trimetazidine, ranolazine was shown to 
promote glucose oxidation, thus improving anaerobic 
metabolism under ischaemic conditions61. Subsequently, 
ranolazine was shown to cause concentration-dependent, 
voltage-dependent, and frequency-dependent inhibition 
of the late sodium current. By inhibiting late sodium 
efflux, ranolazine prevents intracellular calcium overload 
and its deleterious effects60. The therapeutic concentra-
tion needed to reduce calcium overload is similar to that 
at which an increase in glucose oxidation was observed.
Regardless of the main mechanism of action, ranola-
zine has been shown to exert an antianginal action, with 
conflicting results when the immediate-release formula-
tion was used62. Reduction of chronic stable angina occurs 
without affecting heart rate, blood pressure, or myocardial 
perfusion. Under these circumstances, if one excludes a 
possible benefit from an improvement in anaerobic 
metabolism under ischaemic conditions, the only plau-
sible explanation for the antianginal effects is reduced 
left ventricular wall tension and, therefore, a reduction 
in oxygen demand owing to prevention of calcium over-
load during ischaemia60. This property also accounts for 
a prolongation of the corrected QT interval, which leads 
to contraindication of the drug.
Ranolazine has a good safety profile, being devoid 
of any adverse haemodynamic effects when used as 
monotherapy or in combination. Even the dose-related 
prolong ation of the QT interval does not seem to be a 
concern, at least at the recommended therapeutic doses.
Key points for ranolazine:
• A systematic review of randomized, controlled trials 
and a Cochrane meta-analysis concluded that the 
extended-release formulation of 500 mg or 1,000 mg 
of ranolazine is effective in reducing symptoms of 
chronic stable angina, similarly to all the other cur-
rently used antianginal agents60, and its neutral 
 haemodynamic profile could be useful in cases of 
bradycardia and/or hypotension.
• Ranolazine does not improve outcomes of patients 
with chronic stable angina, independently from the 
ventricular function. The recent RIVER-PCI trial63 
enrolled patients with chronic stable angina and 
incomplete revascularization after percutaneous 
coro nary intervention. Ranolazine did not improve 
the primary end point of death, myocardial infarc-
tion, or recurrent chronic stable angina requiring 
further revascularization. Equally, nonbeneficial 
effects (major cardiovascular events, including cardio-
vascular death and myocardial infarction) were 
found in the MERLIN trial64 involving patients with 
non- ST- segment  elevation acute coronary syndrome.
• Ranolazine might be effective in patients with micro-
vascular angina. Following some small, proof-of- 
concept studies suggesting a possible benefit, a larger 
trial was conducted in this specific population 
Table 1 | Drugs for angina: pharmacology, symptom relief, outcomes benefits, and guideline recommendations
Antianginal drug HR SBP DBP PVR CC CV Symptom relief Outcomes benefit ESC* ACC/AHA*
Nitrates
Short‑acting ↑– ↓↓ ↓↓ ↓− – ↑↑↑ Yes No IB IB
Long‑acting ↑− ↓ ↓ ↓− – ↑↑ Yes No IIB IB
β‑Blockers
Noncardioselective ↓↓↓ ↓↓ ↓↓ ↑− ↓↓ – Yes No IA IB
Cardioselective (preserved EF) ↓↓↓ ↓↓ ↓↓ – ↓↓ – Yes No IA IB
Cardioselective (reduced EF) ↓↓↓ ↓↓ ↓↓ – ↓↓ – Yes Yes IB IB
With vasodilatation (preserved EF) ↓↓ ↓↓↓ ↓↓↓ ↓↓ ↓ – Yes No IB IB
With vasodilatation (reduced EF) ↓↓ ↓↓↓ ↓↓↓ ↓↓ ↓ – Yes Yes IA IA
Calcium‑channel blockers
Dihydropyridines ↑− ↓↓↓ ↓↓↓ ↓↓↓ ↑− ↑↑↑ Yes No IA IB
Nondihydropyridines ↓↓ ↓↓ ↓↓ ↓↓ ↓↓ ↑↑ Yes No IA IIB
Other (considered second‑choice treatment in guidelines)
Ivabradine ↓↓ ↓− ↓− – – – Yes No IIaB NA
Nicorandil ↑ ↓↓ ↓↓ ↓− – ↑↑↑ Yes Yes IIaB NA
Ranolazine – – – – – – Yes No IIaB IIA
Trimetazidine – – – – – – Yes No IIbB NA
*Guideline classification of benefit: class I = benefit >>> risk; class IIa = benefit >> risk; class IIb = benefit > risk. Level of evidence: A = one or two large, randomized 
trials; B = one randomized trial or small meta-analysis. CC, cardiac contractility; CV, coronary vasodilatation; DBP, diastolic blood pressure; EF, ejection fraction; 
HR, heart rate; NA, not available; PVR, peripheral vascular resistance; SBP, systolic blood pressure.
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of patients. The results did not show superiority of 
ranolazine compared with placebo on the frequency 
of chronic stable angina or reduction in myo cardial 
ischaemia evaluated by single-photon emission 
 computed tomography65.
• Given the effects on the sodium current and on cal-
cium homeostasis, ranolazine might be more effec-
tive than other drugs in patients with left ventricular 
hypertrophy.
• In patients enrolled in the MERLIN trial64, ranolazine 
significantly reduced glycated haemoglobin (HbA1c) 
levels. Therefore, patients with diabetes and chronic 
stable angina might benefit from ranolazine treatment.
• Ranolazine is contraindicated in patients with hepatic 
impairment or liver cirrhosis. These precautions 
are relevant considering the prolongation of the 
 corrected QT interval. Any accumulation of ranolazine 
must be avoided, because its effects on QT-interval 
 prolongation are dose-dependent60.
• Ranolazine increases digoxin concentration and 
should be used with caution in patients taking digoxin.
Trimetazidine. Trimetazidine is a piperazine derivative. 
As with ranolazine, the exact mechanism of the anti-
anginal action of trimetazidine is not fully understood. 
Trimetazidine increases cellular tolerance to ischaemia 
by inhibiting the mitochondrial 3-ketoacyl-CoA thio-
lase and, consequently, by increasing glucose metabo-
lism. In so doing, trimetazidine directs pyruvate into 
the mitochondria, leading to less proton and lactic acid 
production from the ischaemic myocardium, and more 
anaerobic ATP production from the cytosol. The net 
consequences of these effects are a reduction in free fatty 
acid oxidation and an increase in glucose utilization by 
the ischaemic myocardium66.
These metabolic effects have been confirmed in the 
clinical setting, where treatment with trimetazidine for 
3 months was shown to increase myocardial levels of 
high-energy phosphates by 33% in patients with heart 
failure67. The clinical antianginal effects of trimetazi-
dine have been tested in small and historical studies in 
patients with chronic ischaemia, both as mono therapy 
and as part of a combination regimen, with either 
 calcium-channel blockers or β-blockers68–70.
Generally, treatment-related adverse effects are mild 
and well-tolerated, mostly comprising gastrointestinal 
disturbances such as nausea, vomiting, and minor head-
aches. However, trimetazidine is not recommended in 
patients with Parkinson disease, parkinsonism, and other 
related movement disorders, or in patients with severe 
renal impairment (creatinine clearance <30 ml/min).
Key points for trimetazidine:
• Trimetazidine is a metabolic modulator that does 
not exert haemodynamic effects. Therefore, unlike 
all the other first-line and second-line anti anginal 
agents, trimetazidine does not affect oxygen 
demand, but improves the metabolic efficiency of 
the ischaemic myocytes.
• In a meta-analysis, trimetazidine significantly 
improved exercise tolerance, weekly chronic stable 
angina episodes, and reduced the use of short- acting 
nitrates in comparison with placebo71. The anti angi-
nal effects were similar to those of other antianginal 
agents23.
Guideline recommendations
All guidelines take into consideration evidence provided 
by published trial data and meta-analysis of the differ-
ent studies. However, in absence of these data — which 
unfortunately is not uncommon — the recommenda-
tions are made according to previously reported guide-
lines, tradition-driven beliefs, and opinion of the experts 
on the guideline committees. Some guideline sugges-
tions are inevitably, therefore, not evidence-based. The 
lack of reliable, objective data is indicated by providing 
a lower class to the recommendation.
The absence of objective data is particularly relevant 
to the guidelines for antianginal drug therapy5–8. The 
AHA/ACC2, ESC1, and NICE4 recommendations suggest 
a first-choice therapy with sublingual or short-acting 
nitroglycerin, β-blockers, and calcium-channel blockers. 
Ivabradine, nicorandil, ranolazine, and trimetazidine 
are reserved for patients who have contraindications to 
the first-choice agents, do not tolerate them, or remain 
symptomatic, even though more evidence-based clinical 
data that are more contemporary are available for them 
than for the first-choice drugs.
No head-to-head comparisons between first-choice 
and second-choice treatments are available that demon-
strate superiority of one over any other in terms of 
antianginal effects. Furthermore, double and sometimes 
triple therapy with different classes of anti anginal drugs 
is often needed, and the guidelines do not provide an 
indication of the optimal combination. Nevertheless, the 
 literature and our discussion clearly show that some agents 
have specific properties (in addition to their antianginal 
effect) that allow the selection of the best treatment for the 
specific physiopathology or for the comorbidities and/or 
risk factors. Our ‘ diamond’ approach is a possible frame-
work for individ ualized therapy using the established 
antianginal drugs, which could help clinicians to make 
the best selection of  medications for their patients.
‘Diamond’ approach to treatment
Particular drugs or combinations of drugs are preferred 
for specific physiopathologies or comorbidities (FIGS 4,5).
High heart rate. Heart-rate-lowering agents, such as 
β-blockers, nondihydropyridine calcium-channel block-
ers (diltiazem and verapamil), and ivabradine are the 
preferred drugs when heart rate is >70 bpm. Ivabradine 
can be safely and usefully added to  β-blockers when 
heart rate remains elevated (≥70 bpm)29, but combin-
ing ivabradine with diltiazem or verapamil is clearly 
contra indicated39. Vasodilators, such as dihydropyridine 
calcium-channel blockers and nitrates, are less attrac-
tive because they might increase heart rate. The other 
antianginal drugs can be co-administered, if necessary. 
Combining  β-blockers with diltiazem or verapamil is, 
however, not recommended owing to risk of high- 
degree atrioventricular block. No consensus exists on 
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the optimal heart-rate target. The European Medicines 
Agency recommends that the heart-rate-lowering agents 
should be administered when heart rate is >70 bpm, but 
the dose should be decreased if heart rate remains below 
50–55 bpm (FIG. 4).
Low heart rate. When heart rate is low (≤50–55 bpm), 
heart-rate-slowing agents are clearly contraindicated. 
Preference should be for dihydropyridine calcium- 
channel blockers and nitrates or nicorandil, because 
these might increase heart rate by evoking a sympathetic 
reflex. Other antianginal agents such as ranolazine and 
trimetazidine can be considered (FIG. 4).
Hypertension. β-Blockers and dihydropyridine calcium- 
channel blockers are preferred in hypertension. Blood 
pressure should not be reduced below 130 mmHg sys-
tolic and 80 mmHg diastolic because, in patients with 
coronary artery disease, a clear J-curve phenomenon 
has been demonstrated72. Even in the presence of dia-
betes and other risk factors, no reason exists to adopt an 
aggressive blood-pressure-lowering treatment, as previ-
ously suggested. A meta-analysis showed that in patients 
with diabetes and a baseline systolic blood pressure level 
<140 mmHg, further blood-pressure lowering resulted in 
an increased risk of cardiovascular death73 (FIG. 4).
Hypotension. Agents such as calcium-channel blockers, 
nitrates, and β-blockers that significantly decrease blood 
pressure should not be used in patients with angina and 
low blood pressure, because they might impair coro-
nary perfusion. No validated threshold exists for high 
versus low blood pressure in patients with coronary 
artery disease. Considering the available data, a thresh-
old of 130 mmHg systolic and 80 mmHg diastolic is 
reasonable72,73. In patients with lower blood pressure, 
the use of ivabradine (if associated with a concomitant 
increase in heart rate), ranolazine, or trimetazidine is 
preferable (FIG. 4).
Left ventricular dysfunction and heart failure. When 
chronic stable angina is present in patients with left ven-
tricular systolic dysfunction with or without overt heart 
failure, the overwhelming, evidence-based indication 
is to use β-blockers, which can reduce chronic stable 
angina and, at the same time, effectively reduce cardio-
vascular morbidity and mortality in these patients30,31. 
These beneficial effects seem to be directly correlated 
with a heart-rate-lowering effect of β-blockers; there-
fore, β-blockers with intrinsic sympathetic activity 
should be avoided. If the heart rate remains elevated 
(>70 bpm), despite optimal β-blockade, ivabradine 
should be considered. The SHIFT trial50 showed a 
further prognostic benefit of adding ivabradine to 
evidence-based optimal therapy in patients with overt 
heart failure and reduced ejection fraction. Similar 
benefits were also seen in the subgroup with chronic 
stable angina59. Diltiazem and verapamil should be 
used with caution in this subset of patients because 
they can worsen left ventricular dysfunction74. Finally, 
meta-analysis of small studies of patients with left 
ventricular dysfunction and/or heart failure suggests 
that trimetazidine might be beneficial in addition to 
 recommended therapy75 (FIG. 4).
Atrial fibrillation. Atrial fibrillation might aggrav-
ate anginal symptoms owing to increased heart 
rate. Therefore, agents such as β-blockers and non-
dihydropyridine calcium-channel blockers should be 
preferred when this comorbidity is present. Conversely, 
because of its selectivity for If channels, ivabradine is 
ineffective in patients with atrial fibrillation, and 
might even increase the incidence of the arrhythmia. 
A meta- analysis showed that treatment with ivabradine 
is associ ated with a relative risk of atrial fibrillation of 
1.15 (REF. 76). The SIGNIFY trial39 showed significantly 
more atrial arrhythmias in patients treated with ivabra-
dine (5.3%) versus placebo (3.8%). For these reasons, 
ivabradine is contraindicated in patients with chronic 
stable angina and atrial fibrillation. Dihydropyridine 
calcium- channel antagonists and nitrates or nico-
randil should also be avoided because they can further 
increase heart rate, whereas the other agents can be 
added to  β-blockers to control the symptoms of chronic 
stable angina further. The addition of ranolazine, which 
has been shown to suppress supraventricular arrhyth-
mias and atrial  fibrillation, might be particularly 
useful77,78 (FIG. 4).
Figure 4 | Possible combinations of classes of antianginal drugs according to 
different comorbidities. BB, β-blockers; DHP, dihydropyridine calcium-channel 
blockers; DILT, diltiazem; HR, heart rate; IVAB, ivabradine; NIC, nicorandil; NITR, nitrates; 
RAN, ranolazine; TRIM, trimetazidine; VER, verapamil.
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Diabetes mellitus. Diabetes is often associated with 
coronary atherosclerosis and is considered an ischae-
mic equivalent. Patients with diabetes have a more 
severe ischaemic burden, both symptomatic and silent. 
Treatment of chronic stable angina in these patients 
requires drugs with positive or neutral metabolic 
action. Theoretically, trimetazidine should exert a 
positive action by improving glucose utilization under 
ischaemic conditions. Some positive data are avail able 
in subgroups of patients with diabetes enrolled in trials 
of trimetazidine79. However, these studies are historical, 
involving small numbers of patients with diabetes, and 
often had an open-label design. More evidence-based 
clinical data that are also more contempor ary are avail-
able for ranolazine, which has favourable effects on 
glycated haemoglobin levels80. The efficacy of ranola-
zine in patients with type 2 diabetes and chronic stable 
angina was investigated in a double- blind, placebo- 
controlled trial. Ranolazine signifi cantly reduced 
glycated haemoglobin levels, caused a significant 
reduction in fasting and 2-h postprandial glucose  levels, 
and mitigated the occurrence of angina pain, while 
increasing exercise tolerance81. Ranolazine should, 
therefore, be the preferred approach in this subgroup 
of patients.
Traditionally, β-blockers were considered to facilitate 
new-onset diabetes and aggravate glycaemic control. 
For these reasons, β-blockade is avoided in patients with 
diabetes and chronic stable angina. However, newer 
vaso dilating β-blockers, such as carvedilol and nebivo-
lol, have been reported to improve insulin sensitivity, 
overcoming the metabolic limitation of the traditional 
β-blockers82. All the other antianginal drugs can be used 
to ameliorate the ischaemic burden (FIG. 5).
Chronic kidney disease. Concomitant chronic  kidney 
disease is a risk factor often associated with coronary 
artery disease and has a major effect on outcome and 
therapeutic decision-making. Unfortunately, this group 
of patients is poorly explored in clinical  trials because 
chronic kidney disease is normally an exclusion  criterion. 
Evidence is, therefore, lacking. Ranolazine and trimetazi-
dine should not be prescribed when glomerular filtra-
tion rate is <30 ml/min/1.73 m2. Ranolazine undergoes 
extensive hepatic metabolism by cytochrome P450 and is 
primarily excreted by the kidney. Plasma  levels increase 
up to 50–60% in patients with moderate hepatic or renal 
impairment83. Not surprisingly, given that they belong 
to the same pharmaco logical class, the limitations of 
ranolazine also exist for trimetazidine. Therefore, these 
drugs should not be used in patients with chronic stable 
angina and chronic kidney disease, because they carry 
the risk of further complications. No contraindications 
exist for the use of the other  antianginal drugs (FIG. 5).
Chronic obstructive pulmonary disease. Chronic 
obstructive pulmonary disease is common, shares the 
majority of risk factors with coronary artery disease, 
and is the third leading cause of death84. Observational 
studies have found that patients with chronic obstruc-
tive pulmo nary disease have a threefold increased 
risk of heart failure and twofold increased risk of 
coro nary artery disease84. Historically, β-blockers are 
not recommended because of potential respiratory 
adverse effects; blocking β2-adrenoceptors could lead 
to broncho constriction and worsening lung function. 
Evidence suggests that  β1-selective blockers are gener-
ally well-tolerated in patients with chronic obstruc-
tive pulmonary disease and might improve survival 
and, paradoxically, bronchial responsiveness85. Given 
its high β1-selectivity,  bisoprolol is the only β-blocker 
that is not  contraindicated in chronic obstructive 
pulmonary disease.
Coexistence of asthma, however, is a clear contra-
indication to the use of β-blockers, as is chronic obstruc-
tive pulmonary disease with positive bronchoreactivity. 
In these patients, when treatment of chronic stable 
angina requires reduction of heart rate, ivabradine, 
diltiazem, or verapamil are preferred. For patients with 
chronic stable angina and preserved ventricular func-
tion, the option of calcium-channel blockers or nitrates 
is preferred, because β-blockers will not add any prog-
nostic benefits. In the presence of concomitant pulmo-
nary hypertension with right ventricular dysfunction, 
nondihydropyridine calcium-channel blockers and 
nonselective β-blockers are not recommended (FIG. 5).
Figure 5 | Possible combinations of classes of antianginal drugs according to 
different comorbidities. BB, β-blockers; DHP, dihydropyridine calcium-channel blockers; 
DILT, diltiazem; IVAB, ivabradine; NIC, nicorandil; NITR, nitrates; Non Sel-BB, nonselective 
β-blockers; RAN, ranolazine; Sel-BB, β1-selective blockers; TRIM, trimetazidine; 
VER, verapamil.
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Peripheral artery disease. Intermittent claudication 
is the most common symptom of peripheral athero-
sclerotic disease, and is often associated with chronic 
stable angina, particularly in patients with diabetes86. 
Often, intermittent claudication that limits exercise 
time masks the occurrence of chronic stable angina. 
Patients with peripheral artery disease and chronic 
 stable angina have increased mortality and, therefore, 
need aggressive treatment.
Traditionally, β-blockers were considered to exert 
 general cardioprotection against ischaemia and, there-
fore, also to be effective in patients with concomitant 
peripheral artery disease. This assumption has been 
questioned because of presumed negative peripheral 
haemodynamic consequences of β-blockers, including a 
decrease in cardiac output and unopposed  α-adrenergic 
drive leading to vasoconstriction86,87. In 2013, the British 
Medical Association declared that β-blockers were 
contra indicated in severe peripheral artery disease88. 
The same year, a systematic Cochrane Review provided 
no strong evidence for or against the use of β-blockers in 
peripheral artery disease89. Given the paucity of reliable 
and contemporary data, the consensus of our group is 
that β-blockers should be avoided or used with caution 
in patients with chronic stable angina and peripheral 
artery disease. Equally (and especially in cases of crit-
ical ischaemia), vasodilators such as calcium-channel 
blockers and nitrates should also be avoided because 
acute blood-pressure lowering is deleterious. The 
remaining antianginal drugs (ivabradine, ranolazine, 
and  trimetazidine) are preferred (FIG. 5).
Defects in atrioventricular conduction. Patients with 
chronic stable angina often present with atrio ventricular 
conduction defects of different degrees. β-Blockers and 
nondihydropyridine calcium-channel blockers reduce 
atrioventricular conduction and can even cause a 
complete atrioventricular block and intraventricular 
dyssynchrony90. Therefore, a clear contraindication 
exists for their use in patients with second- degree atrio-
ventricular block. To control symptoms of chronic  stable 
angina,  preference is given to the other  antianginal 
agents (FIG. 5).
Hyperthyroidism. Hyperthyroidism is a pathological 
disorder in which excess thyroid hormones are synthe-
sized and secreted by the thyroid gland. A relationship 
between hyperthyroidism and cardiovascular abnormal-
ity is well known. Patients with hyperthyroidism have 
a threefold increased risk of atrial fibrillation and con-
sequent heart failure91. Thyroid hormone can directly 
affect the factors that determine oxygen consumption of 
the myocardium, leading to the development of chronic 
stable angina in patients with coronary artery disease 
or even with angiographically normal coronary arter-
ies. Thyroid hormones can also cause coronary artery 
spasm92. The preferred treatment in these patients is 
nonselective β-blockers (propanolol), or diltiazem, 
verapa mil, or ivabradine if β-blockers are contra-
indicated. Vasodilators should not be used because of 
the risk of reflex tachycardia (FIG. 5).
Vasospastic angina. The preferred drugs to prevent 
and/or treat coronary artery spasm are undoubtedly 
calcium-channel blockers and long-acting nitrates. 
All calcium-channel blockers can prevent spasm in 
about 90% of patients. Long-acting nitrates are effi-
cacious, but intermittent administration is important 
to prevent nitrate tolerance. β-Blockers are contra-
indicated, because they can precipitate spasm by leaving 
 α-mediated vasoconstriction unopposed by β-mediated 
vasodilatation. In patients with refractory angina, high 
doses of calcium-channel blockers can be tried. In the 
rare patients who are refractory to maximally tolerated 
doses of calcium-channel blockers, sympathectomy is a 
therapeutic option93 (FIG. 5).
Microvascular angina. No conclusive evidence is 
available to support a specific class of drugs, prob-
ably because of the limited knowledge on the causes 
of microvascular angina and the variable response to 
different drug treatments. For many years, traditional 
antianginal drugs, such as β-blockers, calcium- channel 
blockers, and nitrates were considered the only option, 
despite 20–30% of patients remaining symptomatic. 
β-Blockers might be preferred in patients with evi-
dence of increased adrenergic activity1. Ranolazine has 
been suggested to reduce mechanical compression of 
coronary microcirculation94,95. In addition, ranolazine 
might also improve coronary self-regulation96. A small 
trial with ranolazine suggested improvement of angi-
nal symptoms in women with microvascular angina97. 
Subsequently, in a double-blind, placebo-controlled, 
crossover study conducted in women with effort angina 
but no obstructive coronary artery disease, ranolazine 
produced no significant benefits except in some patients 
with impaired coronary flow reserve65. Analogously, 
ivabradine has been shown to improve coronary col-
lateral flow and coronary flow reserve in patients with 
microvascular angina47,48. The effects of ivabradine were 
superior to those of bisoprolol, despite similar degrees 
of heart-rate reduction48. Therefore, treatment of micro-
vascular angina is extremely challenging and necessar-
ily empirical. Slowing the heart rate with β-blockers, 
diltiazem, verapamil, or ivabradine, can be considered 
because of increased diastolic time and coronary perfu-
sion. Co-administration of ranolazine or trimetazidine 
might also be useful. In patients with enhanced pain 
perception, adenosine antagonists and drugs effective in 
chronic pain syndromes, such as imipramine (a tricyclic 
antidepressant), are other therapeutic options.
Conclusions
Given that all antianginal drugs have similar efficacy and 
level of evidence, and no survival benefit, considering 
some drugs but not others to be ‘first choice’ is difficult. 
Furthermore, patients with stable ischaemic heart dis-
ease and chronic stable angina can have several comorbid-
ities, and cardiac ischaemic pain might result from 
various underlying pathophysiologies. Some agents, in 
addition to their antianginal effect, have auxiliary proper-
ties that could be useful, depending on comorbidities 
and the mechanisms of the chronic stable angina.
C O N S E N S U S  S TAT E M E N T
130 | FEBRUARY 2018 | VOLUME 15 www.nature.com/nrcardio
©
 
2018
 
Mac mill an
 
Publishers
 
Li mited,
 
part
 
of
 
Spri nger
 
Nature.
 
All
 
ri ghts
 
reserved. ©
 
2018
 
Mac mill an
 
Publishers
 
Li mited,
 
part
 
of
 
Spri nger
 
Nature.
 
All
 
ri ghts
 
reserved.
1. Task Force Members et al. 2013 ESC guidelines on the 
management of stable coronary artery disease: the 
Task Force on the management of stable coronary 
artery disease of the European Society of Cardiology. 
Eur. Heart J. 34, 2949–3003 (2013).
2. Fihn, S. D. et al. 2012 ACCF/AHA/ACP/AATS/PCNA/
SCAI/STS guideline for the diagnosis and management 
of patients with stable ischemic heart disease: a report 
of the American College of Cardiology Foundation/
American Heart Association Task Force on Practice 
Guidelines, and the American College of Physicians, 
American Association for Thoracic Surgery, Preventive 
Cardiovascular Nurses Association, Society for 
Cardiovascular Angiography and Interventions, and 
Society of Thoracic Surgeons. J. Am. Coll. Cardiol. 60, 
e44–e164 (2012).
3. Mancini, G. B. et al. Canadian Cardiovascular Society 
guidelines for the diagnosis and management of stable 
ischemic heart disease. Can. J. Cardiol. 30, 837–849 
(2014).
4. National Clinical Guidelines Centre. Stable angina: 
methods, evidence & guidance. NICE http:// 
www.nice.org.uk/guidance/cg126/evidence/ 
full-guideline-183176605 (2011).
5. Thadani, U. Management of stable angina — current 
guide lines: a critical appraisal. Cardiovasc. Drugs 
Ther. 30, 419–426 (2016).
6. Camm, A. J. et al. Unresolved issues in the 
management of chronic stable angina. Int. J. Cardiol. 
201, 200–207 (2015).
7. Ambrosio, G. et al. Management of stable angina: 
a commentary on the European Society of Cardiology 
guidelines. Eur. J. Prev. Cardiol. 23, 1401–1412 
(2016).
8. Manolis, A. J. et al. Medical treatment of stable 
angina: a tailored therapeutic approach. Int. J. Cardiol. 
220, 445–453 (2016).
9. Marzilli, M. et al. Obstructive coronary atherosclerosis 
and ischemic heart disease: an elusive link! J. Am. Coll. 
Cardiol. 60, 951–956 (2012).
10. Crea, F., Camici, P. G. & Bairey Merz, C. N. Coronary 
microvascular dysfunction: an update. Eur. Heart J. 
35, 1101–1111 (2014).
11. Stergiopoulos, K. et al. Percutaneous coronary 
intervention outcomes in patients with stable 
obstructive coronary artery disease and myocardial 
ischemia: a collaborative meta-analysis of 
contemporary randomized clinical trials. JAMA Intern. 
Med. 174, 232–240 (2014).
12. McGill, H. C. Jr et al. Association of coronary heart 
disease risk factors with microscopic qualities of 
coronary atherosclerosis in youth. Circulation 102, 
374–379 (2000).
13. Vermeltfoort, I. A. et al. Definitions and incidence of 
cardiac syndrome X: review and analysis of clinical 
data. Clin. Res. Cardiol. 99, 475–481 (2010).
14. Paul, T. K., Sivanesan, K. & Schulman-Marcus, J. Sex 
differences in non obstructive coronary artery disease: 
recent insights and substantial knowledge gaps. 
Trends Cardiovasc. Med. 27, 173–179 (2016).
15. Marinescu, M. A. et al. Coronary microvascular 
dysfunction, microvascular angina, and treatment 
strategies. JACC Cardiovasc. Imaging 8, 210–220 
(2015).
16. Lanza, G. A. & Crea, F. Primary coronary microvascular 
dysfunction: clinical presentation pathophysiology and 
management. Circulation 121, 2317–2325 (2010).
17. Sedlak, T., Izadnegahdar, M., Humphries, K. H. & 
Bairey Merz, C. N. Sex-specific factors in microvascular 
angina. Can. J. Cardiol. 30, 747–755 (2014).
18. Maseri, A. Coronary artery spasm and thrombosis. 
Cardiovascular Clinics, vol 14 No. 1. J. R. Soc. Med. 
78, 178 (1985).
19. Chrysant, S. G. et al. Efficacy and safety of extended-
release isosorbide mononitrate for stable effort angina 
pectoris. Am. J. Cardiol. 72, 1249–1256 (1993).
20. O’Rourke, S. T. Nitro vasodilators: pharmacology 
and use in the treatment of myocardial ischemia. 
Am. J. Pharm. Educ. 66, 177–180 (2002).
21. Thadani, U. & Rodgers, T. Side effects of using nitrates 
to treat angina. Expert Opin. Drug Saf. 5, 667–674 
(2006).
22. Heidenreich, P. A. et al. Meta-analysis of trials 
comparing beta-blockers, calcium antagonists, and 
nitrates for stable angina. JAMA 281, 1927–1936 
(1999).
23. Belsey, J., Savelieva, I., Mugelli, A. & Camm, A. J. 
Relative efficacy of antianginal drugs used as add-on 
therapy in patients with stable angina: a systematic 
review and meta-analysis. Eur. J. Prev. Cardiol. 22, 
837–848 (2015).
24. Salazar, C. A. et al. Ranolazine for stable angina 
pectoris. Cochrane Database Syst. Rev. 2, CD011747 
(2017).
25. Thadani, U. & Opie, L. H. in Drugs for the Heart 
4th edn (ed. Opie, L. H.) 31–48 (Saunders, 1995).
26. Daiber, A. & Münzel, T. Organic nitrate therapy, 
nitrate tolerance, and nitrate-induced endothelial 
dysfunction: emphasis on redox biology and oxidative 
stress. Antioxid. Redox Signal. 23, 899–942 (2015).
27. Husted, S. E. & Ohman, E. M. Pharmacological and 
emerging therapies in the treatment of chronic angina. 
Lancet 386, 691–701 (2015).
28. Thadani, U. et al. Comparison of the immediate effects 
of five beta adrenoreceptor-blocking drugs with 
different ancillary properties in angina pectoris. 
N. Engl. J. Med. 300, 750–755 (1979).
29. Tardif, J. C. et al. Efficacy of the If current inhibitor 
ivabradine in patients with chronic stable angina 
receiving beta-blocker therapy: a 4-month, 
randomized, placebo-controlled trial. Eur. Heart J. 30, 
540–548 (2009).
30. Bangalore, S. et al. Clinical outcomes with beta-
blockers for myocardial infarction: a meta-analysis of 
randomized trials. Am. J. Med. 127, 939–953 (2014).
31. Bangalore, S. et al. β-blocker use and clinical 
outcomes in stable outpatients with and without 
coronary artery disease. JAMA 308, 1340–1349 
(2012).
32. Ferrari, R. Coronary artery disease in 2012: revising 
common beliefs in the management of stable CAD. 
Nat. Rev. Cardiol. 10, 65–66 (2013).
33. Ferrari, R. & Fox, K. Heart rate reduction in coronary 
artery disease and heart failure Nat. Rev. Cardiol. 13, 
493–501 (2016).
34. Andersson, C. et al. β-blocker therapy and cardiac 
events among patients with newly diagnosed coronary 
heart disease. J. Am. Coll. Cardiol. 64, 247–252 
(2014).
35. Booij, H. G. et al. β-blocker therapy is not associated 
with reductions in angina or cardiovascular events 
after coronary artery bypass graft surgery: insights 
from the IMAGINE trial. Cardiovasc. Drugs Ther. 29, 
277–285 (2015).
36. Antman, E. et al. Nifedipine therapy for coronary-
artery spasm: experience in 127 patients. N. Engl. 
J. Med. 302, 1269–1273 (1980).
37. The Multicenter Diltiazem Postinfarction Trial 
Research Group. The effect of diltiazem on mortality 
and reinfarction after myocardial infarction. N. Engl. 
J. Med. 319, 385–392 (1988).
38. Poole-Wilson, P. A. et al. Effect of long-acting 
nifedipine on mortality and cardiovascular morbidity 
in patients with stable angina requiring treatment 
(ACTION trial): randomised controlled trial. Lancet 
364, 849–857 (2004).
39. Fox, K. et al. Ivabradine in stable coronary artery 
disease without clinical heart failure. N. Engl. J. Med. 
371, 1091–1099 (2014).
40. Suryapranata, H. et al. Coronary vasodilatory action 
after a single dose of nicorandil. Am. J. Cardiol. 61, 
292–297 (1988).
41. Gupta, A. K., Winchester, D. & Pepine, C. J. Antagonist 
molecules in the treatment of angina. Expert Opin. 
Pharmacother. 14, 2323–2342 (2013).
42. Camm, A. J. & Maltz, M. B. A controlled single-dose 
study of the efficacy, dose response and duration of 
action of nicorandil in angina pectoris. Am. J. Cardiol. 
63, 61J–65J (1989).
43. Thadani, U. Can nicorandil treat angina pectoris 
effectively? Nat. Clin. Pract. Cardiovasc. Med. 2, 
186–187 (2005).
44. The IONA Study Group. Effect of nicorandil on 
coronary events in patients with stable angina: the 
Impact Of Nicorandil in Angina (IONA) randomised 
trial. Lancet 359, 1269–1275 (2002).
45. Borer, J. S. & Heuzey, J. Y. Characterization of the 
heart rate-lowering action of ivabradine, a selective If 
current inhibitor. Am. J. Ther. 15, 461–473 (2008).
46. Simon, L. et al. Coronary and hemodynamic effects 
of S 16257, a new bradycardic agent, in resting and 
exercising conscious dogs. J. Pharmacol. Exp. Ther. 
275, 659–666 (1995).
47. Gloekler, S. et al. The effect of heart rate reduction 
by ivabradine on collateral function in patients with 
chronic stable coronary artery disease. Heart 100, 
160–166 (2014).
48. Tagliamonte, E. et al. Ivabradine and bisoprolol on 
doppler-derived coronary flow velocity reserve in 
patients with stable coronary artery disease: beyond 
the heart rate. Adv. Ther. 32, 757–767 (2015).
49. Werdan, K. et al. Effectiveness of ivabradine 
treatment in different subpopulations with stable 
angina in clinical practice: a pooled analysis of 
observational studies. Cardiology 135, 141–150 
(2016).
50. Swedberg, K. et al. Ivabradine and outcomes in 
chronic heart failure (SHIFT): a randomised placebo-
controlled study. Lancet 376, 875–885 (2010).
51. Fox, K. et al. Bradycardia and atrial fibrillation in 
patients with stable coronary artery disease treated 
with ivabradine: an analysis from the SIGNIFY study. 
Eur. Heart J. 36, 3291–3296 (2015).
52. Tardif, J. C. et al. Efficacy of ivabradine, a new selective 
If inhibitor, compared with atenolol in patients with 
chronic stable angina. Eur. Heart J. 26, 2529–2536 
(2005).
53. Ruzyllo, W., Tendera, M., Ford, I. & Fox, K. M. 
Antianginal efficacy and safety of ivabradine compared 
with amlodipine in patients with stable effort angina 
pectoris: a 3-month randomised, double-blind, 
multicentre, noninferiority trial. Drugs 67, 393–405 
(2007).
54. Amosova, E. et al. Efficacy of ivabradine in 
combination with beta-blocker versus uptitration of 
beta-blocker in patients with stable angina. 
Cardiovasc. Drugs Ther. 25, 531–537 (2011).
55. European Medicines Agency: Pharmacovigilance Risk 
Assessment Committee (PRAC). Assessment report: 
ivabradine. EMA http://www.ema.europa.eu/docs/en_
GB/document_library/EPAR_-_Assessment_Report_-_
Variation/human/000597/WC500182140.pdf (2014).
56. Fox, K. et al. Ivabradine for patients with stable 
coronary artery disease and left-ventricular systolic 
dysfunction (BEAUTIFUL): a randomised, double-blind, 
placebo-controlled trial. Lancet 372, 807–816 
(2008).
57. Fox, K. et al. Heart rate as a prognostic risk factor 
in patients with coronary artery disease and 
left-ventricular systolic dysfunction (BEAUTIFUL): 
a subgroup analysis of a randomised controlled trial. 
Lancet 372, 817–821 (2008).
58. Fox, K. et al. Relationship between ivabradine 
treatment and cardiovascular outcomes in patients 
with stable coronary artery disease and left ventricular 
systolic dysfunction with limiting angina: a subgroup 
analysis of the randomized, controlled BEAUTIFUL 
trial. Eur. Heart J. 30, 2337–2345 (2009).
During our discussion, we reached a consensus 
that the time has come to propose a different, more 
individualized approach to patients, their comorbid-
ities, and mechanisms of chronic stable angina: the 
‘diamond’ approach. We recognize that drug manage-
ment of patients with chronic stable angina is challeng-
ing, particularly in those with chronic stable angina 
and normal coronary arteries, a condition in which 
considerable work remains to be done to address opti-
mal therapy definitively. We are also aware that the 
issue of reperfusion has not been discussed, and that 
readers might be left with many unanswered ques-
tions, but we hope that our approach will help clin-
icians to make the best possible therapeutic choices, 
 independently of whether the drugs are first or 
second choice.
C O N S E N S U S  S TAT E M E N T
NATURE REVIEWS | CARDIOLOGY  VOLUME 15 |  FEBRUARY 2018 | 131
©
 
2018
 
Mac mill an
 
Publishers
 
Li mited,
 
part
 
of
 
Spri nger
 
Nature.
 
All
 
ri ghts
 
reserved. ©
 
2018
 
Mac mill an
 
Publishers
 
Li mited,
 
part
 
of
 
Spri nger
 
Nature.
 
All
 
ri ghts
 
reserved.
59. Borer, J. S. et al. Efficacy profile of ivabradine in 
patients with heart failure plus angina pectoris. 
Cardiology 136, 138–144 (2016).
60. Rayner-Hartley, E. & Sedlak, T. Ranolazine: 
a contemporary review. J. Am. Heart Assoc. 5, 
e003196 (2016).
61. McCormack, J. G., Barr, R. L., Wolff, A. A. 
& Lopaschuk, G. D. Ranolazine stimulates glucose 
oxidation in normoxic, ischemic, and reperfused 
ischemic rat hearts. Circulation 93, 135–142 (1996).
62. Thadani, U., Ezekowitz, M., Fenney, L. & Chiang, Y. K. 
Double-blind efficacy and safety study of a novel anti-
ischemic agent, ranolazine, versus placebo in patients 
with chronic stable angina pectoris. Circulation 90, 
726–734 (1994).
63. Weisz, G. et al. Use of ranolazine in patients with 
incomplete revascularization after percutaneous 
coronary intervention: design and rationale of the 
Ranolazine for Incomplete Vessel Revascularization 
Post-Percutaneous Coronary Intervention (RIVER-PCI) 
trial. Am. Heart J. 166, 953.e3–959.e3 (2013).
64. Morrow, D. A. et al. Effects of ranolazine on recurrent 
cardiovascular events in patients with non-ST-elevation 
acute coronary syndromes: the MERLIN-TIMI 36 
randomized trial. JAMA 297, 1775–1783 (2007).
65. Bairey Merz, C. N. et al. A randomized, placebo-
controlled trial of late Na current inhibition 
(ranolazine) in coronary microvascular dysfunction 
(CMD): impact on angina and myocardial perfusion 
reserve. Eur. Heart J. 37, 1504–1513 (2016).
66. Kantor, P. F., Lucien, A., Kozak, R. & Lopaschuk, G. D. 
The antianginal drug trimetazidine shifts cardiac 
energy metabolism from fatty acid oxidation to 
glucose oxidation by inhibiting mitochondrial long-
chain 3-ketoacyl coenzyme A thiolase. Circ. Res. 86, 
580–588 (2000).
67. Fragasso, G. et al. Effects of metabolic modulation 
by trimetazidine on left ventricular function and 
phosphocreatine/adenosine triphosphate ratio in 
patients with heart failure. Eur. Heart J. 27, 942–948 
(2006).
68. McClellan, K. J. & Plosker, G. L. Trimetazidine. A 
review of its use in stable angina pectoris and other 
coronary conditions. Drugs 58, 143–157 (1999).
69. Detry, J. M. et al. Trimetazidine: a new concept in the 
treatment of angina. Comparison with propranolol in 
patients with stable angina. Br. J. Clin. Pharmacol. 37, 
279–288 (1994).
70. Peng, S. et al. The efficacy of trimetazidine on stable 
angina pectoris: a meta-analysis of randomized clinical 
trials. Int. J. Cardiol. 177, 780–785 (2014).
71. Xu, X. et al. Effect of trimetazidine on recurrent angina 
pectoris and left ventricular structure in elderly 
multivessel coronary heart disease patients with 
diabetes mellitus after drug-eluting stent 
implantation: a single-centre, prospective, randomized, 
double-blind study at 2-year follow-up. Clin. Drug 
Investig. 34, 251–258 (2014).
72. Vidal-Petiot, E. et al. Cardiovascular event rates and 
mortality according to achieved systolic and diastolic 
blood pressure in patients with stable coronary artery 
disease: an international cohort study. Lancet 388, 
2142–2152 (2016).
73. Tsika, E. P., Poolimenos, L. E., Boudoulas, K. A. 
& Manolis, A. I. The J curve in arterial hypertension: 
fact or fallacy? Cardiology 129, 126–135 (2014).
74. Ponikowski, P. et al. 2016 ESC guidelines for the 
diagnosis and treatment of acute and chronic heart 
failure: the Task Force for the diagnosis and treatment 
of acute and chronic heart failure of the European 
Society of Cardiology (ESC). Developed with the special 
contribution of the Heart Failure Association (HFA) 
of the ESC. Eur. J. Heart Fail. 18, 891–975 (2016).
75. Gao, D., Ning, N., Niu, X., Hao, G. & Meng, Z. 
Trimetazidine: a meta-analysis of randomised 
controlled trials in heart failure. Heart 97, 278–286 
(2011).
76. Martin, R. I. et al. Atrial fibrillation associated with 
ivabradine treatment: meta-analysis of randomised 
controlled trials. Heart 100, 1506–1510 (2014).
77. Scirica, B. M. et al. Effect of ranolazine, an 
antianginal agent with novel electrophysiological 
properties, on the incidence of arrhythmias in 
patients with non ST-segment elevation acute 
coronary syndrome: results from the Metabolic 
Efficiency with Ranolazine for Less Ischemia in 
Non ST-Elevation Acute Coronary Syndrome 
Thrombolysis in Myocardial Infarction 36  
(MERLIN-TIMI 36) randomized controlled trial. 
Circulation 116, 1647–1652 (2007).
78. Reiffel, J. A. et al. The HARMONY trial: combined 
ranolazine and dronedarone in the management 
of paroxysmal atrial fibrillation: mechanistic and 
therapeutic synergism. Circ. Arrhythm. Electrophysiol. 
8, 1048–1056 (2015).
79. Danchin, N., Marzilli, M., Parkhomenko, A. 
& Ribeiro, J. P. Efficacy comparison of trimetazidine 
with therapeutic alternatives in stable angina pectoris: 
a network meta-analysis. Cardiology 120, 59–72 
(2011).
80. Timmis, A. D., Chaitman, B. R. & Crager, M.  
Effects of ranolazine on exercise tolerance and HbA1c 
in patients with chronic angina and diabetes. 
Eur. Heart J. 27, 42–48 (2006).
81. Kosiborod, M. et al. Evaluation of ranolazine in 
patients with type 2 diabetes mellitus and chronic 
stable angina: results from the TERISA randomized 
clinical trial (type 2 diabetes evaluation of ranolazine 
in subjects with chronic stable angina). J. Am. Coll. 
Cardiol. 61, 2038–2045 (2013).
82. Elliott, W. J. & Meyer, P. M. Incident diabetes in 
clinical trials of antihypertensive drugs: a network 
meta-analysis. Lancet 369, 201–207 (2007).
83. Jerling, M. Clinical pharmacokinetics of ranolazine. 
Clin. Pharmacokinet. 45, 469–491 (2006).
84. Schnell, K. et al. The prevalence of clinically relevant 
comorbid conditions in patients with physician-
diagnosed COPD: a cross-sectional study using data 
from NHANES 1999–2008. BMC Pulm. Med. 12, 26 
(2012).
85. Rutten, F. H. et al. Beta-blockers may reduce mortality 
and risk of exacerbations in patients with chronic 
obstructive pulmonary disease. Arch. Intern. Med. 
170, 880–887 (2010).
86. Hiatt, W. R., Stoll, S. & Nies, A. S. Effect of beta-
adrenergic blockers on the peripheral circulation in 
patients with peripheral vascular disease. Circulation 
72, 1226–1231 (1985).
87. George, C. F. Beta-receptor blocking agents. 
Prescribers J. 14, 93–98 (1974).
88. Joint Formulary Committee. British National 
Formulary Vol. 65 (Pharmaceutical Press, 2013).
89. Paravastu, S. C., Mendonca, D. A. & Da Silva, A. 
Beta blockers for peripheral arterial disease. 
Cochrane Database Syst. Rev. 9, CD005508 (2013).
90. Miller, J. M. & Zipes, D. P. in Heart Disease. 
A Textbook of Cardiovascular Medicine 6th edn 
(eds Braunwald, E., Zipes, D. P. & Libby, P.) 711–739 
(Saunders, 2001).
91. De Leo, S., Lee, S. Y. & Braverman, L. E. 
Hyperthyroidism. Lancet 388, 906–918 (2016).
92. Masini, N. D., Northridge, D. B. & Hall, R. J. C. Severe 
coronary vasospasm associated with hyperthyroidism 
causing myocardial infarction. Br. Heart J. 74,  
700–701 (1995).
93. Abbate, A. Sympathectomy as a treatment for 
refractory coronary artery spasm. Int. J. Cardiol. 161, 
e7–e9 (2012).
94. Cattaneo, M., Poretta, A. P. & Gallino, A. Ranolazine: 
drug overview and possible role in primary 
microvascular angina management. Int. J. Cardiol. 
181, 376–381 (2015).
95. Venkataraman, R., Belardinelli, L., Blackburn, B., 
Heo, J. & Iskandrian, A. E. A study of the effects of 
ranolazine using automated quantitative analysis of 
serial myocardial perfusion images. JACC Cardiovasc. 
Imaging 2, 1301–1309 (2009).
96. Tagliamonte, E. et al. Effects of ranolazine on 
noninvasive coronary flow reserve in patients with 
myocardial ischemia but without obstructive coronary 
artery disease. Echocardiography 32, 516–521 
(2015).
97. Mehta, P. K. et al. Ranolazine improves angina in 
women with evidence of myocardial ischemia but no 
obstructive coronary artery disease. JACC Cardiovasc. 
Imaging 4, 514–522 (2011).
98. Maddox, T. M. et al. Angina at 1 year after 
myocardial infarction: prevalence and associated 
findings. Arch. Intern. Med. 168, 1310–1316 
(2008).
99. National Institutes of Health/National Heart, Lung, 
and Blood Institute. Morbidity & Mortality: 2012 
Chart Book on Cardiovascular, Lung, Blood 
Diseases. National Heart, Lung and Blood Institute 
https://www.nhlbi.nih.gov/files/docs/research/ 
2012_ChartBook_508.pdf (2012).
Acknowledgements
This Consensus Statement originated from the University of 
Ferrara through a meeting supported by a grant from 
Fondazione Anna Maria Sechi per il Cuore (FASC), Italy, 
a generous bequest on behalf of Antonio Filippini, and an 
unrestricted educational grant from Servier International. 
FASC and Servier had no role in the preparation of the 
manuscript or the decision to publish.
Author contributions
All authors contributed to researching data, discussion of 
content, and reviewing and editing the manuscript before 
submission. R.F. wrote the manuscript.
Competing interests statement
R.F. has received honoraria for steering committee 
membership and consulting from Novartis and Servier; and for 
speaking and support for travel to study meetings from 
Amgen, Bayer, Boehringer Ingelheim, Merck Serono, and 
Servier. P.G.C. is a consultant for Servier, is part of Board 
meetings of AstraZeneca, and has received speaking honoraria 
from Menarini and Servier. F.C. has received honoraria for 
speaking from BMS, Menarini, Novartis, Sanofi, and Servier; 
and received grants from Biotronik and Boeringher Ingelheim. 
K.F. has received personal fees, honoraria, and/or travel 
expenses from Armgo, AstraZeneca, Broadview Ventures, 
CellAegis, Servier, and TaurX; and is a director of Vesalius Trials 
Ltd. A.P.M. has received honoraria for steering committee 
membership from Bayer, Cardiorentis, and Novartis; received 
support for travel to study meetings from the same companies; 
and received personal fees for speaking activities from Amgen, 
Lilly, Sanofi, and Servier. J.L.L.-S. has received honoraria for 
steering committee membership from AstraZeneca, Bayer, 
Boehringer-Ingelheim, GlaxoSmithKline, Menarini, Merck, 
Novartis, Pfizer, Sanofi, and Servier; received honoraria for 
speaking from Amgen and Sanofi; and received honoraria for 
consultancy from Boehringer Ingelheim and Menarini. The 
other authors declare no competing interests.
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional 
claims in published maps and institutional affiliations.
This work is licensed under 
a   C r e a t i v e  C o m m o n s 
Attribution 4.0 International 
License. The images or other 
third party material in this 
article are included in the article’s Creative Commons license, 
unless indicated otherwise in the credit line; if the material 
is not included under the Creative Commons license, users 
will need to obtain permission from the license holder to 
reproduce the material. To view a copy of this license, visit 
http://creativecommons.org/licenses/by/4.0/.
C O N S E N S U S  S TAT E M E N T
132 | FEBRUARY 2018 | VOLUME 15 www.nature.com/nrcardio
©
 
2018
 
Mac mill an
 
Publishers
 
Li mited,
 
part
 
of
 
Spri nger
 
Nature.
 
All
 
ri ghts
 
reserved.
